{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T09:47:33Z","timestamp":1775814453376,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Clinical trials demonstrating \u03b2-cell protection by high-dose vitamin D supplementation have led to the adoption of adjunctive vitamin D therapy in stage 3 type 1 diabetes (T1D). We present the case of a 12-year-old male child who received high-dose vitamin D therapy from 1\u201327 months following his diagnosis with T1D. His serum 25-hydroxyvitamin D rose from 25 ng\/mL to 65 ng\/dL within 3 months and remained &amp;gt;40 ng\/mL. Hemoglobin A1c (A1c) decreased from 13.8% at diagnosis to persistently &amp;lt;7%. Time in range remained &amp;gt;70% for 24 months, and insulin-dose adjusted A1c (IDAA1c), the clinical marker of partial clinical remission, decreased from 17 to &amp;lt;9 for the duration of therapy. This description of persistence of partial clinical remission (PR), defined as IDAA1c \u22649, for 27 months in a child receiving adjunctive high-dose vitamin D therapy is a build up from our randomized controlled trial of high-dose vitamin D where we demonstrated significant blunting of temporal rise in A1c and IDAA1c over a 12-month period. This prolonged remission by high-dose vitamin D is clinically significant as it positions vitamin D as an affordable therapeutic agent to prolong PR and reduce the short- and long-term complications of T1D. Long-term studies are needed to determine the ultimate duration of these beneficial effects.<\/jats:p>","DOI":"10.3389\/fendo.2026.1788049","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:12:20Z","timestamp":1774930340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["High-dose vitamin D therapy and prolonged partial remission of type 1 diabetes \u2014 a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Adriana","family":"Chader-Gata Garcia","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics, Cohen Children\u2019s Medical Center, Hofstra\/Northwell","place":["Queens, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Cossen","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Children\u2019s Healthcare of Atlanta","place":["Atlanta, GA, United States"]},{"name":"Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Udoka","family":"Nwosu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics, Cohen Children\u2019s Medical Center, Hofstra\/Northwell","place":["Queens, NY, United States"]},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell","place":["Hempstead, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1155","article-title":"Effect of ergocalciferol on \u03b2-cell function in new-onset type 1 diabetes: A secondary analysis of a randomized clinical trial","volume":"7","author":"Nwosu","year":"2024","journal-title":"JAMA network Open"},{"key":"B2","doi-asserted-by":"publisher","first-page":"bvab179","DOI":"10.1210\/jendso\/bvab179","article-title":"Ergocalciferol in new-onset type 1 diabetes: A randomized controlled trial","volume":"6","author":"Nwosu","year":"2022","journal-title":"J Endocrine Soc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.974196","article-title":"Guidance for high-dose vitamin D supplementation for prolonging the honeymoon phase in children and adolescents with new-onset type 1 diabetes","volume":"13","author":"Nwosu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.06.018","article-title":"The pathogenic \u201csymphony\u201d in type 1 diabetes: A disorder of the immune system, beta cells, and exocrine pancreas","volume":"35","author":"Atkinson","year":"2023","journal-title":"Cell Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00223-4","article-title":"Type 1 diabetes","volume":"401","author":"Quattrin","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12413","article-title":"Factors contributing to partial remission in type 1 diabetes: analysis based on the insulin dose-adjusted HbA1c in 3657 children and adolescents from Germany and Austria","volume":"18","author":"Nagl","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12208","article-title":"Partial remission definition: validation based on the insulin dose-adjusted HbA1c (IDAA1C) in 129 Danish children with new-onset type 1 diabetes","volume":"15","author":"Max Andersen","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1987","article-title":"New definition for the partial remission period in children and adolescents with type 1 diabetes","volume":"32","author":"Mortensen","year":"2009","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3067-x","article-title":"The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells","volume":"57","author":"Oram","year":"2014","journal-title":"Diabetologia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.832","article-title":"Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial","volume":"26","author":"Steffes","year":"2003","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1462249","article-title":"The partial clinical remission phase of type 1 diabetes: early-onset dyslipidemia, long-term complications, and disease-modifying therapies","volume":"16","author":"Nwosu","year":"2025","journal-title":"Front Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1624146","article-title":"Editorial: Disease-modifying approaches in type 1 diabetes","volume":"16","author":"Nwosu","year":"2025","journal-title":"Front Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1155","article-title":"Effect of ergocalciferol on beta-cell function in new-onset type 1 diabetes: A secondary analysis of a randomized clinical trial","volume":"7","author":"Nwosu","year":"2024","journal-title":"JAMA network Open"},{"key":"B14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/medsci13030141","article-title":"Combined use of vitamin D and DPP-4 inhibitors as a potential adjuvant treatment strategy to enhance the efficacy of novel beta-cell replacement therapies for type 1 diabetes","volume":"13","author":"Pinheiro","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2865","article-title":"T-lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover","volume":"33","author":"Bogdanou","year":"2017","journal-title":"Diabetes. Metab Res Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.3390\/ijms26104593","article-title":"Type 1 diabetes mellitus and vitamin D","volume":"26","author":"Dur\u00e1-Trav\u00e9","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162554","article-title":"Vitamin D deficiency and glycemic status in children and adolescents with type 1 diabetes mellitus","volume":"11","author":"Savastio","year":"2016","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2022-0044","article-title":"Effects of vitamin D supplementation on glycemic control of children and adolescents with type 1 diabetes mellitus: a systematic review","volume":"35","author":"Nascimento","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1578609","article-title":"Vitamin D for the prevention of diseases in children: A rebuttal to the 2024 Endocrine Society Clinical Practice Guideline","volume":"16","author":"Nwosu","year":"2025","journal-title":"Front Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.977","article-title":"Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA)","volume":"25","author":"Li","year":"2009","journal-title":"Diabetes. Metab Res Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.08.002","article-title":"Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial","volume":"161","author":"Treiber","year":"2015","journal-title":"Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2012.164","article-title":"Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual \u03b2-cell function in new-onset type 1 diabetes mellitus","volume":"166","author":"Gabbay","year":"2012","journal-title":"Arch Pediatr Adolesc. Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0112","article-title":"Partial clinical remission of Type 1 diabetes in Swedish children - A longitudinal study from the Swedish National Quality Register (SWEDIABKIDS) and the Better Diabetes Diagnosis (BDD) study","volume":"26","author":"Fureman","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000819","article-title":"Better HbA1c during the first years after diagnosis of type 1 diabetes is associated with residual C peptide 10 years later","volume":"8","author":"Gronberg","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2063","article-title":"Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial","volume":"329","author":"McVean","year":"2023","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14730","article-title":"A systematic review and meta-analysis of interventions to preserve insulin-secreting beta-cell function in people newly diagnosed with type 1 diabetes: Results from intervention studies aimed at improving glucose control","volume":"39","author":"Narendran","year":"2022","journal-title":"Diabet. Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12657","article-title":"Beta cell function after intensive subcutaneous insulin therapy or intravenous insulin infusion at onset of type 1 diabetes in children without ketoacidosis","author":"Enander","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"20503121241242931","DOI":"10.1177\/20503121241242931","article-title":"Does vitamin D supplementation benefit patients with type 1 diabetes mellitus who are vitamin D deficient? A study was performed at the Sudan Childhood Diabetes Center from 2019 to 2022","volume":"12","author":"Suliman","year":"2024","journal-title":"SAGE Open Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13408","article-title":"Racial and ethnic differences among children with new-onset autoimmune Type 1 diabetes","volume":"34","author":"Gandhi","year":"2017","journal-title":"Diabet. Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2335","article-title":"Racial\/ethnic minority youth with recent-onset type 1 diabetes have poor prognostic factors","volume":"41","author":"Redondo","year":"2018","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196912","article-title":"Children with type 1 diabetes who experienced a honeymoon phase had significantly lower LDL cholesterol 5 years after diagnosis","volume":"13","author":"Nwosu","year":"2018","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7326\/M16-2596","article-title":"Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels","volume":"167","author":"Bergenstal","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1788049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:57:02Z","timestamp":1775811422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1788049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":32,"alternative-id":["10.3389\/fendo.2026.1788049"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1788049","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1788049"}}